409 reports of this reaction
2.7% of all RANOLAZINE reports
#7 most reported adverse reaction
DIZZINESS is the #7 most commonly reported adverse reaction for RANOLAZINE, manufactured by A2A Integrated Pharmaceuticals. There are 409 FDA adverse event reports linking RANOLAZINE to DIZZINESS. This represents approximately 2.7% of all 15,363 adverse event reports for this drug.
Patients taking RANOLAZINE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for RANOLAZINE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for RANOLAZINE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 409 FDA reports for RANOLAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.7% of all adverse event reports for RANOLAZINE, making it a notable side effect.
If you experience dizziness while taking RANOLAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.